STOCKWATCH
·
Pharmaceuticals
Quarterly Result30 May 2025, 07:43 am

Natural Capsules Q4 & FY25 Results: Revenues at 44.97 cr, EBITDA Margin at 9.74%, PAT at 0.52 cr

AI Summary

Natural Capsules Limited, a leading manufacturer of hard capsules shell, has announced its financial results for the fourth quarter and year ended March 31, 2025. The company reported revenues of 44.97 cr for the quarter and 169.21 cr for the year. EBITDA margin stood at 9.74% for the quarter and 10.35% for the year. PAT was reported at 0.52 cr for the quarter and 0.62 cr for the year. The company anticipates improved profitability in the coming quarters due to softening gelatin prices in international markets and a significant price differential between US duties on Chinese and Indian HPMC capsules.

Key Highlights

  • Q4 revenues at 44.97 cr, up 392.62% Q-o-Q and down 46.32% Y-o-Y
  • EBITDA at 4.38 cr, with margins at 9.74% for the quarter and 10.35% for the year
  • PAT at 0.52 cr, with eps at 70.13 for the quarter
  • Anticipated improvement in profitability due to softening gelatin prices and US duty price differential
  • Challenging operating environment in API segment due to industry-wide pressure on product realisations
NATCAPSUQ
Pharmaceuticals
NATURAL CAPSULES LTD.

Price Impact